151106-02-4

Basic information

• Product Name: (E)-7-[3-Bromo-4,5-bis-(4-fluoro-phenyl)-2-isopropyl-pyrrol-1-yl]-5-hydroxy-3-oxo-hept-6-enoic acid methyl ester
• CAS NO: 151106-02-4
• Molecular Weight: 546.409
• Mol File: 151106-02-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (E)-7-[3-Bromo-4,5-bis-(4-fluoro-phenyl)-2-isopropyl-pyrrol-1-yl]-5-hydroxy-3-oxo-hept-6-enoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-7-[3-Bromo-4,5-bis-(4-fluoro-phenyl)-2-isopropyl-pyrrol-1-yl]-5-hydroxy-3-oxo-hept-6-enoic acid methyl ester(151106-02-4)
• EPA Substance Registry System: (E)-7-[3-Bromo-4,5-bis-(4-fluoro-phenyl)-2-isopropyl-pyrrol-1-yl]-5-hydroxy-3-oxo-hept-6-enoic acid methyl ester(151106-02-4)

Safety Data

• Hazardous Substances Data: 151106-02-4(Hazardous Substances Data)

Upstream product

• 105-45-3 acetoacetic acid methyl ester 

Downstream Products

• 151106-12-6 (+/-)-erythro-(E)-7-<3-bromo-4,5-bis(4-fluorophenyl)-2-(1-methylethyl)-1H-pyrrol-1-yl>-3,5-dihydroxy-6-heptenoic acid methyl ester 

Relevant articles and documents

Inhibitors of cholesterol biosynthesis. 2. 3,5-dihydroxy-7-(N-pyrrolyl)- 6-heptenoates, a novel series of HMG-CoA reductase inhibitors

A series of 7-[2,3-diaryl-5-(1-methylethyl)-1H-pyrrol-1-yl]-3,5-dihydroxy- 6-heptenoates was prepared and evaluated for its ability to inhibit the enzyme HMG-CoA reductase in vitro. Maintaining a 5-(1-methylethyl) substituent found to be optimal in related studies, structure-activity relationships were established for compounds modified at positions 2, 3, and 4 of the pyrrole ring. The 4-fluorophenyl group was preferred at the pyrrole 2-position, while incorporation of a range of substituted phenyl groups and pyridyl substituents at the 3-position provided compounds with equivalent enzyme inhibitory activities and widely different lipophilicities. Pentasubstituted pyrrole 3h was found to have a 10-fold greater potency than lovastatin.